# US 2025/0375444 A1 · Method of treating alzheimer’s disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375444 A1
- Document ID: US20250375444A1
- Status: Published application
- Kind: A1
- Application number: 19/211,429
- Filed: 2025-05-19
- Published: 2025-12-11
- Earliest claimed: 2021-05-19
- Assignees: Amyriad Pharma, Inc.
- Applicants: AmyriAD Pharma, Inc.
- Inventors: Sharon L. ROGERS
- Web page: https://patentgrep.com/patent/US20250375444A1

## CPC

- A61K 31/497: containing further heterocyclic rings
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure is directed to the treatment of Alzheimer's disease by administering 1′,3′-dihydro-2H-spiro[imidazo[1,2α]pyridine-3,2′-inden]-2-one orally at a daily dose of 180 mg as a single active agent or co-administered with donepezil hydrochloride and/or memantine hydrochloride.

## Claims

### Claim at position 1

-66. (canceled)

### Claim 67

A method of treating Alzheimer's Disease or dementia of the Alzheimer's type comprising co-administering orally to a human subject a daily dose of 180 mg of 1′,3′-dihydro-2H-spiro[imidazo-[1,2a]pyridine-3,2′-inden]-2-one (“AD101”) and one or more additional therapeutic agents.

### Claim 68 (depends on 67)

A method of claim 67, wherein the one or more additional therapeutic agent is donepezil hydrochloride or memantine hydrochloride.

### Claim 69 (depends on 67)

A method of claim 67, wherein the one or more additional therapeutic agent is donepezil hydrochloride.

### Claim 70 (depends on 69)

The method of claim 69, wherein the subject is already treated with a stable dose of donepezil hydrochloride prior to the first daily dose of AD101.

### Claim 71 (depends on 69)

The method of claim 69, wherein donepezil hydrochloride is administered to the subject at a daily oral dose of 5 mg, 10 mg or 23 mg.

### Claim 72 (depends on 71)

The method of claim 71, wherein donepezil hydrochloride is administered as a film-coated tablet or an orally disintegrating tablet.

### Claim 73 (depends on 71)

The method of claim 71, wherein donepezil hydrochloride is administered at an initial daily dose of 10 mg which is increased to a maintenance daily dose of 23 mg donepezil hydrochloride.

### Claim 74 (depends on 67)

The method of claim 67, wherein AD101 is administered as one or more oral pharmaceutical preparations once-daily (QD).

### Claim 75 (depends on 74)

The method of claim 74, wherein AD101 is administered as:
i) 3 tablets, each tablet comprising 60 mg of AD101;
ii) 2 tablets, each tablet comprising 90 mg of AD101; or
iii) a single tablet comprising 180 mg AD101.

### Claim 76 (depends on 74)

The method of claim 74, wherein AD101 is administered as a single tablet comprising 180 mg AD101.

### Claim 77 (depends on 67)

The method of claim 67, wherein the subject demonstrates an improvement in cognition or overall ability to function in their everyday activities (“global function”) following treatment with AD101.

### Claim 78 (depends on 67)

The method of claim 67, wherein the human subject has a Mini-Mental State Examination (“MMSE”) score of 10 to 24 at the onset of treatment with AD101.

### Claim 79 (depends on 69)

The method of claim 69, wherein the subject is also co-administered memantine hydrochloride.

### Claim 80 (depends on 79)

The method of claim 79, wherein the subject demonstrates an improvement in cognition or overall ability to function in their everyday activities (“global function”) following treatment with AD101.

### Claim 81 (depends on 67)

The method of claim 67, wherein the daily dose of 180 mg of AD101 is comprised in one or more oral pharmaceutical preparations with one or more excipients or carriers.

### Claim 82 (depends on 81)

The method of claim 81, wherein the oral pharmaceutical preparation is a tablet.

### Claim 83 (depends on 82)

The method of claim 82, wherein the tablet has an enteric coating.

### Claim 84 (depends on 81)

The method of claim 81, wherein the oral pharmaceutical preparation is a capsule.

### Claim 85 (depends on 84)

The method of claim 84, wherein the capsule has an enteric coating.
